Registry of female precocious puberty, aiming identification of predisposing factors, optimization of treatment strategy, and elucidation of prognosis

Registry of female precocious puberty, aiming identification of predisposing factors, optimization of treatment strategy, and elucidation of prognosis - Precocious puberty registry

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044400

Enrollment

100

Registered

2021-06-03

Start date

2021-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

female central precocious puberty

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Female patients who will be diagnosed with central precocious puberty (gonadotropin-dependent precocious puberty) at Department of Pediatrics, Showa University Hospital after July 2021.

Exclusion criteria

Exclusion criteria: 1) premature thelarche 2) central precocious puberty with organic origin 3) gonadotropin-independent precocious puberty

Design outcomes

Primary

Measure	Time frame
1) Information collected at the time of diagnosis: family history, maternal information during pregnancy, perinatal history, past history, social history, growth data, physical findings, endocrine test (LH, FSH, E2, DHEA-S, TSH, Free T3, Free T4, IGF-1), Bone age, ultrasonic findings of uterus and ovary, MRI findings in hypothalamo-pituitary region 2) Information collected during follow-up or treatment For non-treatment patients: growth data, physical findings, bone age (every 6 months to 1 year until menarche) For patients with LHRH analog treatment: growth data, physical findings, endocrine test, bone age, ultrasonic findings, treatment details 3) Information to be collected after the completion of treatment growth data, physical findings, endocrine tests, ultrasonography (6-months and one year following the cessation)	—

Measure

Time frame

1) Information collected at the time of diagnosis: family history, maternal information during pregnancy, perinatal history, past history, social history, growth data, physical findings, endocrine test (LH, FSH, E2, DHEA-S, TSH, Free T3, Free T4, IGF-1), Bone age, ultrasonic findings of uterus and ovary, MRI findings in hypothalamo-pituitary region 2) Information collected during follow-up or treatment For non-treatment patients: growth data, physical findings, bone age (every 6 months to 1 year until menarche) For patients with LHRH analog treatment: growth data, physical findings, endocrine test, bone age, ultrasonic findings, treatment details 3) Information to be collected after the completion of treatment growth data, physical findings, endocrine tests, ultrasonography (6-months and one year following the cessation)

—

Secondary

Measure	Time frame
Serum will be cryopreserved for each patient.	—

Countries

Japan

Contacts

Public ContactMasanori Adachi

Showa University School of Medicine Department of Pediatrics

m0adachi@med.showa-u.ac.jp03-3784-8565

Outcome results